Status:
RECRUITING
Electrical Stimulation for the Treatment of Optic Neuropathies
Lead Sponsor:
Stanford University
Conditions:
Glaucoma
Glaucoma, Open-Angle
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is ...
Detailed Description
This is a concurrent open-label study for patients who are deemed safe to participate in the electrical stimulation trial but do not fit the exact criteria for the randomized clinical trial.
Eligibility Criteria
Inclusion Criteria:
- Participant must be at least 18.
- Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
- Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%.
- In the opinion of the investigator the participant's eye pressure must be clinically stable.
- If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.
- Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
Exclusion Criteria:
- Participant is unable to comply with study procedures or follow-up visits.
- Participant has a history of ocular herpes zoster.
- Participant has pathological nystagmus
- Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.
- Participant has evidence of corneal opacification or lack of optical clarity.
- Participant has uveitis or other ocular inflammatory disease.
- Participant has any electric or electroinc implants such as a pacemaker.
- Participant has acute conjunctivitis.
- Participant has acute autoimmune disease.
- Participant is pregnant or lactating.
- Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.
- Unresected brain tumors
- Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable
- Patients with any skin damage.
- Children and comatose patients.
- Patients with history of epileptic seizure within the last 10 years.
- Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
- Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation
- Prior participation in a vision training/stimulation study in the last 12 months
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05626426
Start Date
February 27 2023
End Date
December 1 2027
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Byers Eye Institute
Palo Alto, California, United States, 94303